NCT06161051View on ClinicalTrials.gov

Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

CompletedOBSERVATIONAL
Enrollment

287

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

November 2, 2022

Study Completion Date

December 7, 2022

Conditions
Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY